Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021
August 23, 2021 at 11:25 am
Share
Regenicin, Inc. announced earnings results for the third quarter ended June 30, 2021. For the third quarter, the company announced operating loss was USD 155,559 compared to USD 162,054 a year ago. Net loss was USD 165,345 compared to USD 171,838 a year ago. For the nine months, operating loss was USD 532,113 compared to USD 517,262 a year ago. Net loss was USD 558,527 compared to USD 558,472 a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
REGENICIN, INC. 